Roche Venture Fund

The Roche Venture Fund is the corporate venture capital arm of Roche, a global leader in healthcare and pharmaceuticals. With an evergreen fund of CHF 750 million, the fund focuses on investing in life sciences, particularly in pharmaceuticals, diagnostics, and digital health sectors. The fund’s mission is to foster innovation and build commercially successful companies while generating financial returns for Roche. They typically make Series A investments, with initial checks ranging from CHF 5-10 million and a 15-20% equity stake. Roche Venture Fund is active globally, with offices in Basel, Switzerland, and South San Francisco, USA, providing access to a wide network of industry experts and strategic guidance to portfolio companies. Notable investments include companies like Freenome, Black Diamond Therapeutics, and Syapse, which are leaders in fields like diagnostics and precision medicine. The fund offers more than just financial backing, involving themselves deeply in the growth and development of their portfolio companies. This hands-on approach ensures startups benefit from Roche’s vast resources and expertise in navigating the complexities of the life sciences market. Their long-term vision and commitment to innovation make them a preferred partner for biotech and healthtech startups looking to make a significant impact.